6月1日,中国生物制药(01177)发布公告,旗下附属公司正大天晴药业集团股份有限公司两项重磅创新药临床研究数据,于2026年美国临床肿瘤学会(ASCO)年会正式公布,涵盖肺癌一线治疗与全球首个EGFR/c-Met双抗ADC两大领域,疗效与安全性数据双双亮眼,彰显公司在肿瘤创新药领域的硬核实力。 贝莫苏拜单抗联合安罗替尼III期数据出炉,显著延长非鳞NSCLC患者PFS 此次ASCO年会上,...
Source Link6月1日,中国生物制药(01177)发布公告,旗下附属公司正大天晴药业集团股份有限公司两项重磅创新药临床研究数据,于2026年美国临床肿瘤学会(ASCO)年会正式公布,涵盖肺癌一线治疗与全球首个EGFR/c-Met双抗ADC两大领域,疗效与安全性数据双双亮眼,彰显公司在肿瘤创新药领域的硬核实力。 贝莫苏拜单抗联合安罗替尼III期数据出炉,显著延长非鳞NSCLC患者PFS 此次ASCO年会上,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.